



09/138,209

March 27, 2000



chain nodes :

12 13 14 15 16 20 21 26

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 27 28 29 30 31 32

ring/chain nodes :

22

chain bonds :

2-11 3-12 5-13 13-14 14-15 15-16 15-26 20-21

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 27-28 27-32
28-29 29-30 30-31 31-32

exact/norm bonds :

1-2 1-5 2-3 2-11 3-4 3-12 4-5 5-13 13-14 14-15 15-16 15-26
20-21 27-28 27-32 28-29 29-30 30-31 31-32

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

isolated ring systems :

containing 1 :

G1:H, [*1], [*2]

G2:N, CH2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS
20:CLASS 21:CLASS 22:CLASS 26:CLASS 27:Atom 28:Atom 29:Atom
30:Atom

31:Atom 32:om 33:CLASS

=> d 18

L8 HAS NO ANSWERS

L7 STR



G1 H, [01], [02]

G2 N, CH2

Structure attributes must be viewed using STN Express query preparation.

L8 QUE ABB=ON PLU=ON L7

=> d bib abs hitstr 1-2 111

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1997:579718 CAPLUS

DN 127:248104

TI Preparation of aryloxooxazolidinylmethylacetamides and related compounds as antibacterials.

IN Gravestock, Michael Barry

PA Zeneca Ltd., UK; Gravestock, Michael Barry

SO PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9730995	A1	19970828	WO 1997-GB462	19970220
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,				

IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG

AU 9718053	A1	19970910	AU 1997-18053	19970220
EP 882042	A1	19981209	EP 1997-903509	19970220
R: CH, DE, FR, GB, IT, LI				
JP 11514662	T2	19991214	JP 1997-529888	19970220
US 5981528	A	19991109	US 1997-945160	19971021
PRAI GB 1996-3939		19960224		
GB 1996-18404		19960904		
WO 1997-GB462		19970220		
OS MARPAT 127:248104				
GI				



AB Title compds. (I; R1 = OH, Cl, Br, F, alkylsulfonyloxy, amino, N3, alkoxy, alkylthio, alkylaminocarbonyloxy, etc.; R2, R3 = H, F; D = O, S, SO, SO2, imino, acylimino; R4, R5 = H, Br, O, alkyl, alkanoylaminoalkyl, hydroxyalkyl, CO2H, alkoxycarbonyl, etc.; R6 = H, alkyl, OH, alkoxy, alkanoyloxy; AB = C:CRa, CHCHRa, or C(OH)CHRa; Ra = H, alkyl), were prepd.

Thus, a mixt. of tert-Bu 1,2,3,6-tetrahydro-4-(trifluoromethylsulfonyloxy)pyridine-1-carboxylate, Pd2(dibenzylideneacetone)2, Ph3As, and LiCl in N-methylpyrrolidine was treated with (S)-5-acetamidomethyl-3-(4-trimethyltinphenyl)oxazolidin-2-one (prepn. given) followed by stirring at room temp. to 40.degree. to give 23% (S)-N-[3-[4-(1-tert-butyloxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide. The latter showed a min.

inhibitory concn. of 1.0 .mu.g/mL against Staphylococcus aureus Oxford.

IT 188974-28-9P 188974-31-4P 188974-49-4P
188974-50-7P 188974-66-5P 188974-69-8P
188974-70-1P 188974-72-3P 188976-05-8P
195816-21-8P 195816-22-9P 195816-23-0P
195816-24-1P 195816-26-3P 195816-27-4P
195816-28-5P 195816-29-6P 195816-30-9P
195816-31-0P 195816-32-1P 195816-33-2P
195816-34-3P 195816-36-5P 195816-37-6P
195816-38-7P 195816-39-8P 195816-40-1P
195816-41-2P 195816-42-3P 195816-44-5P
195816-47-8P 195816-50-3P 195816-52-5P
195816-65-0P 195816-67-2P 195816-68-3P
195816-70-7P 195816-72-9P 195816-90-1P
195816-91-2P 195816-92-3P 195816-93-4P
195816-94-5P 195816-95-6P 195816-96-7P
195816-97-8P 195816-98-9P 195816-99-0P
195817-00-6P 195817-02-8P 195817-04-0P

195817-05-1P 195817-06-2P 195817-07-3P
 195817-08-4P 195817-09-5P 195817-10-8P
 195817-11-9P 195817-12-0P 195817-13-1P
 195817-14-2P 195817-15-3P 195817-16-4P
 195817-17-5P 195817-18-6P 195817-19-7P
 195817-20-0P 195817-21-1P 195817-22-2P
 195817-23-3P 195817-24-4P 195817-25-5P
 195817-26-6P 195817-27-7P 195817-28-8P
 195817-29-9P 195817-30-2P 195817-31-3P
 195817-32-4P 195817-33-5P 195817-34-6P
 195817-35-7P 195817-36-8P 195817-37-9P
 195817-38-0P 195817-39-1P 195817-40-4P
 195817-41-5P 195817-42-6P 195817-43-7P
 195817-44-8P 195817-45-9P 195817-46-0P
 195817-47-1P 195817-48-2P 195817-49-3P
 195817-50-6P 195817-51-7P 195817-52-8P
 195817-53-9P 195817-54-0P 195817-55-1P
 195817-56-2P 195817-57-3P 195817-58-4P
 195817-79-9P 195830-15-0P 195830-81-0P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryloxooxazolidinylmethylacetamides and related compds. as antibacterials)

RN 188974-28-9 CAPLUS

CN Acetamide, N-[[3-[4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-31-4 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 188974-49-4 CAPLUS

CN Acetamide,

N-[[3-[[4-[[1-[(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-50-7 CAPLUS

CN Acetamide, N-[[3-[[3-fluoro-4-[1,2,3,6-tetrahydro-1-(hydroxyacetyl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-66-5 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(1-formyl-1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-69-8 CAPLUS

CN Acetamide, N-[[3-[4-[1-[(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-70-1 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(hydroxyacetyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-72-3 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188976-05-8 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-, 1,1-dimethylethyl ester, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 195816-21-8 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-oxazolidinyl]methyl]-, (S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 188974-68-7
 CMF C17 H21 N3 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 195816-22-9 CAPLUS
 CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(methylsulfonyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195816-23-0 CAPLUS

CN Acetamide,


N-[[3-[3-fluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 188974-48-3


CMF C17 H20 F N3 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 195816-24-1 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195816-26-3 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(methoxyacetyl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195816-27-4 CAPLUS

CN Acetamide,

N-[[3-[[4-[[1-(1,2-dioxopropyl)-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-28-5 CAPLUS


CN 1(2H)-Pyridinecarboxamide, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-N-ethyl-3,6-dihydro-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195816-29-6 CAPLUS
 CN Acetamide,
 N-[[3-[4-[1-(1,3-dioxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl]-3-
 fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195816-30-9 CAPLUS
 CN Acetamide, N-[[3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-[[2-(2-
 methoxyethoxy)ethoxy]acetyl]-4-pyridinyl]phenyl]-2-oxo-5-
 oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-31-0 CAPLUS

CN Acetamide, N-[[3-[[4-[1-[(acetylamino)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-32-1 CAPLUS

CN Butanoic acid, 3-oxo-, 2-[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,6-dihydro-1(2H)-pyridinyl]-2-oxoethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195816-33-2 CAPLUS

CN Acetamide,

N-[[3-[[3-fluoro-4-[1,2,3,6-tetrahydro-1-[1-oxo-3-(phenylamino)-2-butenyl]-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 195816-34-3 CAPLUS

CN Acetamide, N-[[3-[[4-(1-cyano-1,2,3,6-tetrahydro-4-pyridinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-36-5 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(2-pyrimidinyl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-37-6 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(1H-tetrazol-5-yl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-38-7 CAPLUS

CN Acetamide, N-[[3-[[3-fluoro-4-[[1,2,3,6-tetrahydro-1-(methylsulfonyl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-39-8 CAPLUS

CN Acetamide, N-[[3-[[4-[[1-[(decyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-40-1 CAPLUS

CN Butanoic acid, 2-[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]-2-oxoethyl ester, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-41-2 CAPLUS

CN Decanoic acid, 2-[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]-2-oxoethyl ester, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-42-3 CAPLUS

CN Carbamic acid, ethyl-, 2-[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]-2-oxoethyl ester, (S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195816-44-5 CAPLUS

CN Acetic acid, (phenylmethoxy)-, 2-[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-

oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]-2-oxoethyl ester, (S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-47-8 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(2-hydroxy-1-oxodecyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-50-3 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(2-pyrimidinyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-52-5 CAPLUS

CN Acetamide,
N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(4-methylphenyl)sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-65-0 CAPLUS

CN Acetic acid, hydroxy-, 2-[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-1-piperidiny]-2-oxoethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-67-2 CAPLUS

CN Acetamide,
N-[3-[3,5-difluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195816-68-3 CAPLUS

CN Acetamide,

N-[[3-[[3,5-difluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)-, mono(trifluoroacetate) (9CI) (CA

INDEX


NAME)

CM 1

CRN 195816-67-2


CMF C17 H19 F2 N3 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 195816-70-7 CAPLUS
CN Acetamide,
N-[[3-[4-[1-[(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]-
3,5-difluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, (S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 195816-72-9 CAPLUS
CN Acetamide, N-[[3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(hydroxyacetyl)-4-
pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-, (S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 195816-90-1 CAPLUS

CN Acetamide,

N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[[2-methyl-3-(nitromethyl)-5-oxocyclopentyl]acetyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, [1R-[1.alpha.(S*),2.beta.,3.alpha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 195816-91-2 CAPLUS

CN Acetamide, N-[[3-[4-[1-(butoxyacetyl)-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195816-92-3 CAPLUS

CN Acetamide,

N-[[3-[4-[1-[(5-fluoro-1H-indol-3-yl)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195816-93-4 CAPLUS


CN Acetamide, N-[[3-[4-[1-[(3-acetyl-2,2-dimethylcyclobutyl)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [1(S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 195816-94-5 CAPLUS

CN Acetamide, N-[[3-[4-[1-(2-cyclopenten-1-ylacetyl)-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-95-6 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(2-naphthalenyloxy)acetyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-96-7 CAPLUS

CN 1(2H)-Pyridineacetamide, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-.alpha.-oxo-, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-97-8 CAPLUS

CN Carbamic acid, [2-[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-98-9 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(methylthio)acetyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195816-99-0 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-00-6 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(trifluoroacetyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-02-8 CAPLUS

CN Acetamide,

N-[[3-[4-[1-[3-(2-furanyl)-1-oxo-2-propenyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 195817-04-0 CAPLUS

CN Acetamide, N-[[3-[4-[1-(3-furanylcarbonyl)-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-05-1 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[1-oxo-3-(2-thienyl)-2-propenyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 195817-06-2 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(2-thienylacetyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-07-3 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(3-thienylcarbonyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-08-4 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(1H-indol-3-ylacetyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-09-5 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(2-pyrimidinylthio)acetyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-10-8 CAPLUS

CN Acetamide, N-[[3-[4-[1-[(3,4-dihydro-2H-pyran-2-yl)carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-11-9 CAPLUS

CN Acetamide,

N-[[2-oxo-3-[[4-[[1,2,3,6-tetrahydro-1-[(5-methoxy-4-oxo-4H-pyran-2-yl)carbonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 195817-12-0 CAPLUS

CN Acetamide,

N-[[3-[4-[1-[(2,3-dihydro-1,4-benzodioxin-6-yl)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 195817-13-1 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[1-oxo-3-(phenylsulfonyl)propyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-14-2 CAPLUS


CN Acetamide, N-[[3-[4-[1-[4-(aminosulfonyl)benzoyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 195817-15-3 CAPLUS
 CN Acetamide, N-[[3-[4-[1-[4-[(diethylamino)sulfonyl]benzoyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 195817-16-4 CAPLUS

CN Acetamide,

N-[[3-[4-[1-[4-(dimethylamino)-1-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-17-5 CAPLUS

CN Acetamide, N-[[3-[4-[1-[(1-acetyl-2-pyrrolidinyl)carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-18-6 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[1-oxo-3-(2,3,4-trimethoxyphenyl)-2-propenyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 195817-19-7 CAPLUS
 CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(tetrahydro-5-oxo-2-furanyl)carbonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195817-20-0 CAPLUS
 CN Acetamide, N-[[3-[4-[1-(1,7-dioxooctyl)-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-21-1 CAPLUS

CN Acetamide, N-[[3-[4-[1-(2-benzofuranylcarbonyl)-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-22-2 CAPLUS


CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(1H-indol-1-ylacetyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-23-3 CAPLUS
 CN Acetamide,
 N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(tetrahydro-1,1-dioxido-3-thienyl)acetyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (5S)-(9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 195817-24-4 CAPLUS
 CN Acetamide,
 N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(4-oxo-4H-1-benzopyran-2-yl)carbonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-25-5 CAPLUS

CN Acetamide,

N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(1H-indol-3-ylcarbonyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-26-6 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[[2-(propylthio)-3-pyridinyl]carbonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-27-7 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(2-methoxy-3-pyridinyl)carbonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-28-8 CAPLUS

CN Acetamide, N-[[3-[4-[1-[(2,3-dihydro-5-oxo-5H-thiazolo[3,2-a]pyrimidin-6-yl)carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-29-9 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(8-quinolinylsulfonyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-30-2 CAPLUS

CN Acetamide,
N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(2-naphthalenylsulfonyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-31-3 CAPLUS


CN Benzoic acid, 2-[[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]-, methyl ester,
(S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 195817-32-4 CAPLUS
 CN Acetamide, N-[[3-[4-[1-[(4-fluorophenyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195817-33-5 CAPLUS
 CN Acetamide, N-[[3-[4-[1-[(3-chloropropyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-34-6 CAPLUS

CN Acetamide, N-[[3-[4-[1-[(4-chlorophenyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-35-7 CAPLUS

CN Benzoic acid, 4-[[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-36-8 CAPLUS

CN Acetamide,

N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(1-methylethyl)sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-37-9 CAPLUS


CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(2-phenylethenyl)sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 195817-38-0 CAPLUS
CN Acetamide, N-[[3-[4-[1-(ethylsulfonyl)-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-39-1 CAPLUS
CN Acetamide, N-[[3-[4-[1-(butylsulfonyl)-1,2,3,6-tetrahydro-4-

pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-40-4 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(octylsulfonyl)-4-pyridinyl]phenyl]-5-oxazolidinyl)methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-41-5 CAPLUS

CN Acetamide, N-[[3-[4-[1-[(2-chlorophenyl)sulfonyl]-1,2,3,6-tetrahydro-4-


pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 195817-42-6 CAPLUS

CN Benzoic acid, 3-[[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-43-7 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-44-8 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(2,2,2-trifluoroethyl)sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-45-9 CAPLUS

CN Acetamide,

N-[[3-[[4-[1-[(5-chloro-2-thienyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-46-0 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[[5-(2-pyridinyl)-2-thienyl)sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-47-1 CAPLUS

CN Acetamide,


N-[[3-[4-[1-[(2,4-difluorophenyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 195817-48-2 CAPLUS
 CN Acetamide, N-[[3-[4-[1-[(3-fluorophenyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195817-49-3 CAPLUS
 CN Acetamide, N-[4-[[4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]phenyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-50-6 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-51-7 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[[5-(3-isoxazolyl)-2-thienyl]sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-52-8 CAPLUS

CN Acetamide,

N-[[3-[4-[1-[(5-bromo-2-thienyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-53-9 CAPLUS

CN Acetamide, N-[[3-[4-[1-[(4-cyanophenyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-54-0 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-55-1 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-[[4-(trifluoromethyl)phenyl]sulfonyl]-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-56-2 CAPLUS

CN Acetamide,


N-[[3-[4-[1-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 195817-57-3 CAPLUS

CN Acetamide, N-[[3-[4-[1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195817-58-4 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(phenylsulfonyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195817-79-9 CAPLUS

CN Acetamide,

N-[[3-[[4-(3,6-dihydro[1(2H),2'-bipyridin]-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195830-15-0 CAPLUS

CN Acetamide,

N-[[3-[[3-fluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-2-oxo-

5-oxazolidinyl)methyl]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 195830-81-0 CAPLUS

CN Acetamide,

N-[[3-[4-[1-[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-, [1(S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 188975-28-2P 195817-63-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of aryloxoxazolidinylmethylacetamides and related compds. as
antibacterials)

RN 188975-28-2 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-
oxazolidinyl]-2-fluorophenyl]-3,6-dihydro-, 1,1-dimethylethyl ester, (S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195817-63-1 CAPLUS
 CN Carbamic acid,
 acetyl[[3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-
 4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl
 ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS
 AN 1997:302929 CAPLUS
 DN 126:277463
 TI Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic
 rings,
 and their use as antimicrobials.
 IN Hutchinson, Douglas K.; Ennis, Michael D.; Hoffman, Robert L.; Thomas,
 Richard C.; Poel, Toni-Jo; Barbachyn, Michael Robert; Brickner, Steven
 J.;
 Anderson, David J.
 PA Upjohn Co., USA; Hutchinson, Douglas, K.; Ennis, Michael D.; Hoffman,
 Robert L.; Thomas, Richard C.; Poel, Toni-Jo; Barbachyn, Michael Robert;
 Brickner, Steven J.; Anderson, David J.
 SO PCT Int. Appl., 110 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9709328	A1	19970313	WO 1996-US12766	19960813
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				

CA 2228647	AA	19970313	CA 1996-2228647	19960813
AU 9667181	A1	19970327	AU 1996-67181	19960813
EP 856002	A1	19980805	EP 1996-927316	19960813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1197457	A	19981028	CN 1996-197155	19960813
BR 9610474	A	19990302	BR 1996-10474	19960813
JP 11512386	T2	19991026	JP 1996-511190	19960813
FI 9800452	A	19980227	FI 1998-452	19980227
NO 9800855	A	19980430	NO 1998-855	19980227
PRAI US 1995-3149	19950901			
WO 1996-US12766	19960813			
OS MARPAT 126:277463				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. of formula I, or their pharmaceutically acceptable salts, are claimed [wherein X = NR₁, S(O)g, or O; R₁ = H, C₁-6 alkyl

[(un)substituted

with 1 or more OH, cyano, or halo], arylalkyl, acyl, CO₂H or derivs., acyl, heterocyclyl, etc.; R₂ = H, C₁-6 alkyl, aralkyl, halo; R₃, R₄ = H

or

halo; R₅ = H, C₁-12 (halo)alkyl, C₃-12 cycloalkyl, C₁-6 alkoxy; m, n = 0-5; (m+n) = 1-5]. The compds. are useful as antimicrobial agents. For instance, Et cyanoacetate was arylated with 3,4-F₂C₆H₃NO₂ and alkylated with MeI (100%), followed by hydrogenation of the nitrile and nitro

groups

(97%), cyclization to an azetidinone (60%), redn. of the amide carbonyl, protection of both ring and sidechain N atoms as the di-Cbz deriv. (51%), lithiation with BuLi, and reaction with (R)-glycidyl butyrate (64%), to give intermediate alc. II. This alc. was converted to its mesylate ester (100%), which was ammonolyzed, followed by N-acetylation (84%), hydrogenolysis (99%), and reaction with Me chloroformate (77%), to give title compd. III. This compd. had an ED₅₀ comparable to vancomycin (5.00 mg/kg vs. 3.00 mg/kg, resp.) against Staphylococcus aureus, in vivo in mice.

IT 188975-11-3P 188975-20-4P 188975-26-0P

188975-28-2P 188975-59-9P 188975-64-6P

188975-70-4P 188975-72-6P 188976-05-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(intermediate; prepn. of (heterocyclylphenyl)oxazolidinone derivs. as antibacterials)

RN 188975-11-3 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




14a)

RN 188975-20-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188975-26-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,6-difluorophenyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188975-28-2 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,6-dihydro-, 1,1-dimethylethyl ester, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188975-59-9 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 3-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-5,6-dihydro-, 1,1-dimethylethyl ester, (S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 188975-64-6 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 5-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,4-dihydro-, phenylmethyl ester, (S)-(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 188975-70-4 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(4-fluoro-4-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188975-72-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-fluoro-, phenylmethyl ester, (S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 188976-05-8 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-, 1,1-dimethylethyl ester, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT 188974-26-7P 188974-27-8P 188974-29-0P
 188974-30-3P 188974-40-5P 188974-41-6P
 188974-42-7P 188974-45-0P 188974-46-1P
 188974-48-3P 188974-49-4P 188974-68-7P
 188974-69-8P 188974-80-3P 188974-82-5P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);


SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (heterocyclphenyl)oxazolidinone derivs. as antibacterials)

RN 188974-26-7 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-(4-piperidinyl)phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




Ex 17 in provisional

RN 188974-27-8 CAPLUS

CN Acetamide,

N-[[2-oxo-3-[4-[1-[(phenylmethoxy)acetyl]-4-piperidinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




Ex. 18

14c

RN 188974-29-0 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(4-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




20

RN 188974-30-3 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1-[(phenylmethoxy)acetyl]-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

(NAME)

Absolute stereochemistry. Rotation (-).



21

RN 188974-40-5 CAPLUS

CN 1-Piperidinecarboxylic acid,


4-[4-[5-[[[(dichloroacetyl)amino]methyl]-2-oxo-

3-oxazolidinyl]-2-fluorophenyl]-, 1,1-dimethylethyl ester, (S)- (9CI)

(CA

INDEX NAME)

Absolute stereochemistry. Rotation (-).




30

RN 188974-41-6 CAPLUS

CN Acetamide, 2,2-dichloro-N-[[3-[3-fluoro-4-(4-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




31

RN 188974-42-7 CAPLUS

CN Acetamide,
N-[[3-[4-[1-[(acetyloxy)acetyl]-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-dichloro-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




32

RN 188974-45-0 CAPLUS

CN Acetamide, N-[[3-[3,5-difluoro-4-(4-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




35

RN 188974-46-1 CAPLUS

CN Acetamide, N-[[3-[3,5-difluoro-4-[1-[(phenylmethoxy)acetyl]-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




36

RN 188974-48-3 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



38

RN 188974-49-4 CAPLUS
 CN Acetamide,
 N-[[3-[4-[1-[(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]-
 3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry. Rotation (-).



39

RN 188974-68-7 CAPLUS
 CN Acetamide, N-[[2-oxo-3-[4-(1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-5-
 oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



58

RN 188974-69-8 CAPLUS
 CN Acetamide, N-[[3-[4-[1-[(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



59

RN 188974-80-3 CAPLUS
 CN Acetamide,
 N-[[3-[4-[1-[(acetyloxy)acetyl]-1,2,5,6-tetrahydro-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 188974-82-5 CAPLUS

CN Acetamide,

N-[[3-[[4-[[1-[(acetyloxy)acetyl]-1,4,5,6-tetrahydro-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 188974-28-9P 188974-31-4P 188974-32-5P
 188974-33-6P 188974-34-7P 188974-35-8P
 188974-36-9P 188974-37-0P 188974-38-1P
 188974-43-8P 188974-44-9P 188974-47-2P
 188974-50-7P 188974-66-5P 188974-67-6P
 188974-70-1P 188974-71-2P 188974-72-3P
 188974-81-4P 188974-83-6P 188974-84-7P
 188974-95-0P 188974-96-1P 188974-97-2P

188974-98-3P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (heterocyclphenyl)oxazolidinone derivs. as antibacterials)

RN 188974-28-9 CAPLUS

CN Acetamide, N-[[3-[4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-31-4 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




22

RN 188974-32-5 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1-(1H-indol-2-ylcarbonyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




23

RN 188974-33-6 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1-(5-isoxazolylcarbonyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




24

RN 188974-34-7 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1-(methylsulfonyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




25

RN 188974-35-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



26

RN 188974-36-9 CAPLUS
 CN Acetamide,
 N-[[3-[4-[1-(cyanomethyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-
 5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



27

RN 188974-37-0 CAPLUS
 CN Acetamide, N-[[3-[3-fluoro-4-[1-(2-fluoroethyl)-4-piperidinyl]phenyl]-2-
 oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




28

RN 188974-38-1 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(1-formyl-4-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




29

RN 188974-43-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[[3-[3-fluoro-4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




33

RN 188974-44-9 CAPLUS

CN Acetamide,

N-[[3-[4-[1-[(acetyloxy)acetyl]-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




34

RN 188974-47-2 CAPLUS

CN Acetamide,

N-[[3-[3,5-difluoro-4-[1-(hydroxyacetyl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




37

RN 188974-50-7 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(hydroxyacetyl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




40

RN 188974-66-5 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(1-formyl-1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-67-6 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3,6-dihydro-, methyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-70-1 CAPLUS

CN Acetamide, N-[[2-oxo-3-[4-[1,2,3,6-tetrahydro-1-(hydroxyacetyl)-4-pyridinyl]phenyl]-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



60

RN 188974-71-2 CAPLUS
 CN Acetamide,
 N-[[3-[4-(1-formyl-1,2,3,6-tetrahydro-4-pyridinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



61

RN 188974-72-3 CAPLUS
 CN 1(2H)-Pyridinecarboxylic acid, 4-[4-[5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-3,6-dihydro-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




62

RN 188974-81-4 CAPLUS

CN Acetamide, N-[[3-[[3-fluoro-4-[1,2,5,6-tetrahydro-1-(hydroxyacetyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188974-83-6 CAPLUS

CN Acetamide, N-[[3-[[3-fluoro-4-[1,4,5,6-tetrahydro-1-(hydroxyacetyl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-84-7 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(4-fluoro-1-formyl-4-piperidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188974-95-0 CAPLUS

CN Acetamide, N-[[3-[4-[1-(4,5-dihydro-4-oxo-2-thiazolyl)-4-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 188974-96-1 CAPLUS

CN Acetamide,

N-[[3-[4-[1-(4,5-dihydro-4-oxo-2-thiazolyl)-1,2,5,6-tetrahydro-3-pyridinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-97-2 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1-(5-methyl-1,3,4-thiadiazol-2-yl)-4-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 188974-98-3 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-[1,2,5,6-tetrahydro-1-(5-methyl-1,3,4-thiadiazol-2-yl)-3-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



158

11